Glioma Stem Cells—Features for New Therapy Design

Author:

Pećina-Šlaus Nives12ORCID,Hrašćan Reno3

Affiliation:

1. Laboratory of Neuro-Oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Šalata 12, 10000 Zagreb, Croatia

2. Department of Biology, School of Medicine, University of Zagreb, Šalata 3, 10000 Zagreb, Croatia

3. Department of Biochemical Engineering, Faculty of Food Technology and Biotechnology, University of Zagreb, 10000 Zagreb, Croatia

Abstract

On a molecular level, glioma is very diverse and presents a whole spectrum of specific genetic and epigenetic alterations. The tumors are unfortunately resistant to available therapies and the survival rate is low. The explanation of significant intra- and inter-tumor heterogeneity and the infiltrative capability of gliomas, as well as its resistance to therapy, recurrence and aggressive behavior, lies in a small subset of tumor-initiating cells that behave like stem cells and are known as glioma cancer stem cells (GCSCs). They are responsible for tumor plasticity and are influenced by genetic drivers. Additionally, GCSCs also display greater migratory abilities. A great effort is under way in order to find ways to eliminate or neutralize GCSCs. Many different treatment strategies are currently being explored, including modulation of the tumor microenvironment, posttranscriptional regulation, epigenetic modulation and immunotherapy.

Funder

University of Zagreb

Publisher

MDPI AG

Reference151 articles.

1. Exploration of involved key genes and signaling diversity in brain tumors;Nasser;Cell Mol. Neurobiol.,2017

2. Impact of age and gender on glioblastoma onset, progression, and management;Colopi;Mech. Ageing Dev.,2023

3. Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. (2016). WHO Classification of Tumours of the Central Nervous System, The International Agency for Research on Cancer. [4th ed.].

4. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary;Louis;Neuro Oncol.,2021

5. Molecular Pathology of Tumors of the Central Nervous System;Kristensen;Ann. Oncol.,2019

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. GBM immunotherapy: Exploring molecular and clinical frontiers;Life Sciences;2024-11

2. Biopsy of Brain Lesions;Veterinary Clinics of North America: Small Animal Practice;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3